The “U.S. Oligonucleotide Synthesis Market Size, Share & Trends Analysis Report” for 2024-2030 has been added to ResearchAndMarkets.com’s portfolio. This report forecasts that the U.S. oligonucleotide synthesis market will reach USD 3.09 billion by 2030, growing at a CAGR of 12.80% from 2024 to 2030.
The surge in demand for molecular diagnostics, innovative applications, and oligonucleotide therapeutics for treating conditions such as cardiovascular diseases, retinal disorders, and cancer is expected to drive market growth. The COVID-19 pandemic has further boosted the industry, as pharmaceutical companies and healthcare professionals sought to enhance oligonucleotide applications to combat the virus. For example, the Innovative Genomic Institute developed a nasal spray using locked nucleic acid-modified antisense oligonucleotides to treat COVID-19, showcasing the pandemic’s positive impact on the market.
In addition, investments in oligonucleotide-based therapeutics are increasing. In October 2023, GSK plc and Arrowhead Pharmaceuticals secured a deal with Janssen Pharmaceuticals for the development and commercialization of JNJ-3989. Such initiatives by major pharmaceutical companies are expected to further propel market growth.
However, challenges remain, such as the need for advanced oligo synthesis solutions and the high cost of genomic research. Real-time monitoring of synthesis efficiency is crucial, as even minor errors can significantly impact long sequences.
Market Highlights:
- Services led the product & service segment with a 37.34% revenue share in 2023, driven by the increasing demand for specialized services in genomic research.
- PCR Primers held the largest market share in 2023, essential for detecting minute quantities of DNA or RNA. Sequencing is projected to grow the fastest.
- Academic Research Institutes led the end-use segment with a 43.16% revenue share in 2023, due to rising clinical studies and research funding. Pharmaceutical & Biotechnology Companies are expected to grow at the fastest CAGR.
Key Companies:
- Thermo Fisher Scientific, Inc.
- Merck KGaA
- Danaher Corporation
- Dharmacon Inc.
- Agilent Technologies
- Bio-synthesis
- LGC Biosearch Technologies
- Twist Bioscience
- TriLink BioTechnologies
- Genscript
Report Details:
- Pages: 90
- Forecast Period: 2023-2030
- 2023 Market Value: $1.36 Billion
- 2024-2030 CAGR: 12.8%
- Regions Covered: United States
Chapters Include:
- Methodology and Scope
- Executive Summary
- Market Variables, Trends, & Scope
- Product & Service Business Analysis
- Application Business Analysis
- End-use Business Analysis
- Competitive Landscape
